For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink: https://www.kuickresearch.com/report-global-immune-check-point-inhibitors-market-and-clinical-pipeline-insight-2022.php
Table of Contents
-
Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy
1.1 Overview
1.2 History- From Tragedy to Breakthrough
-
Major Immune Checkpoints Proteins
2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development
2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development
-
Mechanism of Action of Immune Checkpoint Inhibitors
3.1 Cytotoxic T lymphocyte Antigen-4 (CTLA-4)
3.1 Programed Death Protein-1 (PD1)
-
CTLA 4 Inhibition Approved Drugs to Target Immune Checkpoints
4.1 Ipilimumab (Yervoy: Melanoma)
-
PD-1 and PD-L1 Inhibition Approved Drugs to Target Immune Checkpoints
5.1 Nivolumab (Opdivo: Hodgkin Lymphoma, Urothelial Carcinoma and NSCLC)
5.2 Pembrolizumab (Keytruda: Melanoma and NSCLC)
5.3 Atezolizumab (Tecentriq: Solid Tumors)
-
Biomarkers Associated with Immune Checkpoint Inhibitors
6.1 Predictive Biomarkers to Anti-CTLA 4
6.2 Predictive Biomarker to Anti-PD 1
-
Combination Approaches with Immune Checkpoint Inhibitors
7.1 Combination with Conventional Methods
7.1.1 Chemotherapy
7.1.2 Targeted Therapies
7.1.3 Radiotherapy
7.2 Combination with Cancer Vaccines
7.2.1 Peptide Vaccines
7.2.2 Cellular Vaccines
7.2.3 Oncolytic Viruses
-
Global Immune Checkpoint Inhibitors Market
-
Global Immune Checkpoint Inhibitors Clinical Pipeline
9.1 CTLA-4-Inhibitors Pipeline Overview
9.2 PD-1-Protein-Inhibitors Pipeline Overview
9.3 PD-1-Protein-Inhibitors Pipeline Overview
-
Global Immune Checkpoint Inhibitors Market Dynamics
10.1 Favorable Parameters
10.2 Challenges to Market Growth
-
Future Potential of Immune Checkpoint Inhibitors
11.1 Current Therapeutic Eminence
11.2 Upcoming Market Opportunities
-
PDL1-Protein-Inhibitors Clinical Pipeline by Company, Indication and Phase
12.1 Research
12.2 Preclinical
12.3 Clinical
12.4 Phase-I
12.5 Phase-I/II
12.6 Preregistration
-
Marketed PDL1-Protein-Inhibitors Clinical Insight by Company and Phase
13.1 Pembrolizumab (Keytruda)
13.2 Atezolizumab (TECENTRIQ)
-
CTLA-4-Inhibitors Clinical Pipeline by Company, Indication and Phase
14.1 Research
14.2 Preclinical
14.3 Phase-I
14.4 Phase-III
-
Marketed CTLA-4-Inhibitors Clinical Insight by Company, Phase and Indication
15.1 Ipilimumab (Yervoy)
-
PD-1-Protein-Inhibitors Clinical Pipeline by Company, Phase and Indication
16.1 Research
16.2 Preclinical
16.3 Phase-I
16.4 Phase-I/II
16.5 Phase-II
16.6 Phase-II/III
-
Marketed PD-1-Protein-Inhibitors Clinical Insight by Company and Phase
17.1 Pembrolizumab (Keytruda)
-
Competitive Landscape
18.1 Advaxis
18.2 Agenus
18.3 Amgen
18.4 Bristol Myers Squibb
18.5 Faron Pharmaceuticals
18.6 Genentech
18.7 Genocea
18.8 Incyte Corporation
18.9 Innate Pharma
18.10 Kite Pharma
18.11 MacroGenics
18.12 Merck
18.13 NewLink Genetics Corp
18.14 Sorrento Therapeutics
18.15 TG Therapeutics
Figure 1-1: History of Immune Checkpoint Inhibitors
Figure 2-1: Types of Immune Checkpoint Proteins
Figure 2-2: Cytotoxic T Cell Lymphocyte in Cancer Development
Figure 2-3: Programmed Death Protein in Cancer Development
Figure 3-1: Mechanism of Action of Cytotoxic T lymphocyte Antigen- 4
Figure 3-2: Mechanism of Action of Programmed Death Protein-1
Figure 4-1: Categorization of Approved Drugs to Target Immune Checkpoints
Figure 4-2: Yervoy andndash; Global Revenue (US$ Million), 2015 andndash; 2016 and 2022
Figure 4-3: Yervoy andndash; US Revenue (US$ Million), 2015 and 2016
Figure 5-1: Opdivo andndash; Global Revenue (US$ Million), 2015 and 2016 and 2022
Figure 5-2: Opdivo andndash; US Revenue (US$ Million), 2015 and 2016
Figure 5-3: Keytruda andndash; Global Revenue (US$ Million), 2015-2016 and 2022
Figure 5-4: Tecentriq andndash; Global Revenue (US$ Million), 2015-2022
Figure 7-1: Combination Approaches with Immune Checkpoint Inhibitors used in Treatment
Figure 8-1: Global – Share of Immune Checkpoint Inhibitors in Cancer Immunotherapy Market, 2015-2022 (%)
Figure 8-2: Global – Immune Checkpoint Inhibitors Market (US$, Billion), 2016-2022
Figure 9-1: CTLA-4-Inhibitors Clinical Pipeline by Phase (%), 2017 till 2022
Figure 9-2: CTLA-4-Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 9-3: PD-1-Protein-Inhibitors Pipeline by Phase (%), 2017 till 2022
Figure 9-4: PD-1-Protein-Inhibitors Pipeline by Phase (Number), 2017 till 2022
Figure 9-5: PD-1-Protein-Inhibitors Pipeline by Phase (%), 2017 till 2022
Figure 9-6: PD-1-Protein-Inhibitors Pipeline by Phase (Number), 2017 till 2022
Figure 10-1: Accelerating Parameters for Global Immune Checkpoint Inhibitors Market
Figure 10-2: Barriers to Global Immune Checkpoint Inhibitors Market Growth
Table 6-1: Possible Biomarkers Used in Treatment with Anti-CTLA-4
Table 6-2: Potential Biomarker Used in Treatment with Anti-PD-1
Table 10-1: Immune Checkpoint Inhibitors Marketed and Pipeline